论文部分内容阅读
目的 :观察前列腺素E1(PGE1)对肝炎肝硬变患者血清透明质酸 (HA)、层粘连蛋白 (LN)、肿瘤坏死因子α(TNF α)的影响。方法 :采用PGE1治疗 5 3例肝炎肝硬变患者 ,选择 5 3例进行综合基础治疗的肝炎肝硬变患者作为对照组 ,应用放免法测定治疗前后患者血清HA、LN、TNF α水平。结果 :治疗组中ChildA、B级患者血清HA、LN较对照组有显著下降 (P <0 .0 1) ,ChildA级患者血清TNF α水平较对照组亦有显著下降 (P <0 .0 1)。结论 :PGE1治疗肝炎肝硬变 ,对肝功能损害不严重的ChildA、B级患者尤其是ChildA级患者有抗纤维化作用。
Objective: To observe the effects of prostaglandin E1 (PGE1) on serum hyaluronic acid (HA), laminin (LN) and tumor necrosis factor α (TNF α) in patients with liver cirrhosis. Methods: Fifty-three patients with cirrhosis of liver cirrhosis were treated with PGE1. Fifty-three patients with hepatocirrhosis who underwent basic treatment were selected as the control group. Serum levels of HA, LN and TNFα were measured by radioimmunoassay before and after treatment. Results: The serum levels of HA and LN in ChildA and B patients in the treatment group were significantly lower than those in the control group (P <0.01). The levels of serum TNFα in ChildA patients were significantly lower than those in the control group (P <0.01) ). Conclusion: PGE1 is effective in treating cirrhosis of the liver and antifibrotic effects in ChildA and B patients, especially in ChildA patients with impaired hepatic function.